Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.

[en] BACKGROUND: Our aim is to report treatment efficacy and toxicity of patients treated by robotic (Cyberknife®) stereotactic body radiotherapy (SBRT) for oligorecurrent lung metastases (ORLM). Additionally we wanted to evaluate influence of tumor, patient and treatment related parameters on local control (LC), lung and distant progression free- (lung PFS/Di-PFS) and overall survival (OS). METHODS: Consecutive patients with up to 5 ORLM (confirmed by FDG PET/CT) were included in this study. Intended dose was 60Gy in 3 fractions (prescribed to the 80% isodose volume). Patients were followed at regular intervals and tumor control and toxicity was prospectively scored. Tumor, patient and treatment data were analysed using competing risk- and Cox regression. RESULTS: Between May 2010 and March 2016, 104 patients with 132 lesions were irradiated from primary lung carcinoma (47%), gastro-intestinal (34%) and mixed primary histologies (19%). The mean tumor volume was 7.9 cc. After a median follow up of 22 months, the 1, 2 and 3 year LC rate (per lesion) was 89.3, 80.0 and 77.8% respectively. The corresponding (per patient) 1, 2 and 3 years lung PFS were 66.3, 50.0, 42.6%, Di-PFS were 80.5, 64.4, 60.6% and OS rates were 92.2, 80.9 and 72.0% respectively. On univariable analysis, gastro-intestinal (GI) as primary tumor site showed a significant superior local control versus the other primary tumor sites. For OS, significant variables were primary histology and primary tumor site with a superior OS for patients with metastases of primary GI origin. LC was significantly affected by the tumor volume, physical and biologically effective dose coverage. Significant variables in multivariable analysis were BED prescription dose for LC and GI as primary site for OS. The vast majority of patients developed no toxicity or grade 1 acute and late toxicity. Acute and late grade 3 radiation pneumonitis (RP) was observed in 1 and 2 patients respectively. One patient with a centrally located lesion developed grade 4 RP and died due to possible RT-induced pulmonary hemorrhage. CONCLUSIONS: SBRT is a highly effective local therapy for oligorecurrent lung metastases and could achieve long term survival in patients with favourable prognostic features.

Disciplines :

Radiology, nuclear medicine & imaging

Author, co-author :

Berkovic, Patrick

GULYBAN, Akos

Defraene, Gilles

Swenen, Laurie

Dechambre, David

NGUYEN, Paul Viet

Jansen, Nicolas ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

MIEVIS, Carole ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de radiothérapie

LOVINFOSSE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Département de Physique Médicale > Service médical de médecine nucléaire et imagerie onco

Janvary, Levente

Lambrecht, Maarten

De Meerleer, Gert

Language :

English

Title :

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.

Publication date :

2020

Journal title :

BMC Cancer

eISSN :

1471-2407

Publisher :

BioMed Central, London, United Kingdom

Volume :

Issue :

Pages :

402

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 22 June 2020

Statistics

Number of views

63 (8 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37-49.
Treasure T, Milosevic M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014:1-4.
Van Raemdonck D, Friedel G. The European Society of Thoracic Surgeons lung Metastasectomy project. J Thorac Oncol. 2010;5(6):127-9.
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378-82.
Boyer MJ, Ricardi U, Ball D, Salama JK. Ablative approaches for pulmonary metastases. Thorac Surg Clin. 2016;26(1):19-34.
Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013;31(11):1384-90.
Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32(26):2902-12.
Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28-37.
Shultz DB, Filippi AR, Thariat J, Mornex F, Loo BW, Ricardi U. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol. 2014;9(10):1426-33.
Lancia A, Ingrosso G, Carosi A, Di Murro L, Giudice E, Cicchetti S, et al. Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis. Acta Oncol (Madr). 2017;56(11):1621-5.
Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107-11.
Yamashita H, Niibe Y, Yamamoto T, Katsui K, Jingu K, Kanazawa S, et al. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol. 2016;46(7):687-91.
Inoue T, Katoh N, Onimaru R, Shirato H. Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of Oligo-recurrence. Pulm Med. 2012;2012:1-5.
Sloth Møller D, Knap MM, Nyeng TB, Khalil AA, Holt MI, Kandi M, et al. Difference in target definition using three different methods to include respiratory motion in radiotherapy of lung cancer. Acta Oncol. 2017;56(11):1604-9.
Boda-Heggemann J, Frauenfeld A, Weiss C, Simeonova A, Neumaier C, Siebenlist K, et al. Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. Radiat Oncol. 2014;9:10.
Nuyttens JJ, Van De Pol M. The CyberKnife radiosurgery system for lung cancer. Expert Rev Med Devices. 2012;9(5):465-75.
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Vol. 21, The Lancet Oncology. Lancet Publishing Group. 2020:e18-28.
Kuduvalli G. Multiple Fiducial identification using the hidden Markov model in image guided radiosurgery. Conf Comput Vis Pattern Recognit Work. 2006;2006:92.
Janvary ZL, Jansen N, Baart V, Devillers M, Dechambre D, Lenaerts E, et al. Clinical outcomes of 130 patients with primary and secondary lung tumors treated with Cyberknife robotic stereotactic body radiotherapy. Radiol Oncol. 2017;51(2):178-86.
Berkovic P, Gulyban A, Nguyen PV, Dechambre D, Martinive P, Jansen N, et al. Stereotactic Robotic Body Radiotherapy for Patients With Unresectable Hepatic Oligorecurrence. Clin Colorectal Cancer. 2017;16(4).
Timmerman RD. An overview of Hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215-22.
Dechambre D, Janvary LZ, Jansen N, Berkovic P, Mievis C, Baart V, et al. Prediction of GTV median dose differences eases Monte Carlo re-prescription in lung SBRT. Phys Medica. 2018;45.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
Dept of Health and Human Services U. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health. 2009.
Treasure T, Fallowfield L, Lees B. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. J Thorac Oncol. 2010;5(6 Suppl 2):S203-6.
Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):7S-37S.
Høyer M, Swaminath A, Bydder S, Lock M, Méndez Romero A, Kavanagh B, et al. Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys. 2012;82(3):1047-57.
Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11(1).
Park JJ, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron JJ, et al. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017;56(12):1746-53.
Rieber J, Streblow J, Uhlmann L, Flentje M, Duma M, Ernst I, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases - A pooled analysis of the German working group "stereotactic radiotherapy.". Lung Cancer. 2016;97:51-8.
Sharma A, Duijm M, Oomen-de Hoop E, Aerts JG, Verhoef C, Hoogeman M, et al. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol (Madr). 2018;28:1-7.
Helou J, Thibault I, Poon I, Chiang A, Jain S, Soliman H, et al. Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter. Int J Radiat Oncol. 2017;98(2):419-27.
Binkley MS, Trakul N, Jacobs LR, Von Eyben R, Le QT, Maxim PG, et al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):1044-52.
Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF. Lung metastases treated with stereotactic ablative radiation therapy in Oligometastatic colorectal Cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer. 2017;16(1):58-64.
Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol. 2016;118:485-91.
Yamamoto T, Jingu K, Shirata Y, Koto M, Matsushita H, Sugawara T, et al. Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors. BMC Cancer. 2014;14:464.
Siva S, Slotman BJ. Stereotactic ablative body radiotherapy for lung metastases: where is the evidence and what are we doing with it? Semin Radiat Oncol. 2017;27(3):229-39.
Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJM, Langendijk JA. Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol. 2013;107(3):409-13.
Palma DA, Olson R, Harrow S, Gaede S, Louie A V, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. www.thelancet.com. 2019;393.
Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Jack Lee J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558-65.
Niibe Y, Yamashita H, Sekiguchi K, Takahashi W, Shiraishi K, Okuma K, et al. Stereotactic body radiotherapy results for pulmonary Oligometastases: a two-institution collaborative investigation. Anticancer Res. 2015;35(9):4903-8.
Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res. 2016;57(1):55-61.
Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H. Editorial Oligometastases/Oligo-Recurrence of Lung Cancer; 2013. p. 438236.
Sharma A, Duijm M, Oomen-de Hoop E, Aerts JG, Verhoef C, Hoogeman M, et al. Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol (Madr). 2019;58(1):74-80.
Tekatli H, Tetar SU, Nguyen TK, Warner A, Verbakel WF, Palma DA, et al. Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy. Acta Oncol. 2017;56(4):548-54.
Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 2013;19(3):200-7.